Journal for Research in Applied Sciences and Biotechnology

www.jrasb.com

ISSN: 2583-4053

Volume-3 Issue-1 || February 2024 || PP. 154-158

https://doi.org/10.55544/jrasb.3.1.25

Bilirubin Nanomedicines for the Treatment of Reactive Oxygen Species (ROS)-Mediated Diseases

Yash Gupta[1], Riya Shikha[2], Vishal Rai[3], Nisha Bano[4], Soban khan[5] and Reena Yadav[6]

[1,2,3,4,5,6]Department of Pharmacy, Dr. M.C. Saxena College of Pharmacy, Uttar Pradesh, INDIA.

[1]Corresponding Author: yashguptamehul@gmail.com

www.jrasb.com || Vol. 3 No. 1 (2024): February Issue

Received: 30-01-2024 **Revised:** 03-02-2024 **Accepted:** 05-02-2024

ABSTRACT

Bilirubin, a natural product of heme catabolism, has recently emerged as a promising candidate in nanomedicine for the treatment of Reactive Oxygen Species (ROS)-mediated diseases. ROS, including free radicals and other oxygen-derived molecules, play a pivotal role in various pathological conditions such as inflammation, neurodegenerative disorders, and cardiovascular diseases. Bilirubin's potent antioxidant properties make it an attractive therapeutic agent, and recent advancements in nanotechnology have paved the way for its effective delivery and application in treating ROS-related ailments. This abstract delves into the potential of bilirubin-based nanomedicines in combating ROS-induced damage. The encapsulation of bilirubin within nanocarriers enhances its stability, bioavailability, and targeted delivery to affected tissues. The utilization of nanoscale systems not only safeguards bilirubin from degradation but also allows for controlled release, ensuring sustained therapeutic effects. The multifaceted mechanisms of bilirubin action include its ability to scavenge free radicals, modulate inflammatory responses, and protect cellular components from oxidative stress. The encapsulation of bilirubin in nanoparticles further improves its pharmacokinetics, enabling efficient distribution and accumulation at disease sites. Moreover, the nanocarrier systems can be engineered to respond to specific stimuli, facilitating site-specific release of bilirubin in response to the elevated ROS levels characteristic of pathological conditions. This abstract also highlights the versatility of bilirubin nanomedicines in addressing diverse ROS-mediated diseases. From neuroprotection in conditions like Alzheimer's and Parkinson's diseases to alleviating oxidative stress in cardiovascular disorders, bilirubin-based nanotherapeutics exhibit a broad spectrum of applications. The tailored design of nanocarriers allows for personalized treatment approaches, catering to the unique characteristics of each disease state.

Keywords- Bilirubin, Heme catabolism, Reactive Oxygen Species (ROS).

I. INTRODUCTION

Reactive Oxygen Species (ROS)-mediated diseases pose a significant challenge in contemporary healthcare due to their involvement in diverse pathological conditions, ranging from inflammatory disorders to neurodegenerative diseases and cardiovascular ailments(1). The detrimental impact of ROS, including free radicals and other oxygen-derived species, on cellular structures and functions necessitates innovative therapeutic approaches that can effectively mitigate oxidative stress(2).

Bilirubin, a natural product derived from the breakdown of heme, has garnered attention as a potent endogenous antioxidant with the capacity to counteract ROS-induced damage. Recent advancements in nanomedicine have opened avenues for harnessing the therapeutic potential of bilirubin in a targeted and controlled manner(3).Encapsulation of bilirubin within nanocarriers not only enhances its stability but also facilitates precise delivery to affected tissues, addressing challenges associated with its administration(4).

ISSN: 2583-4053
Volume-3 Issue-1 || February 2024 || PP. 154-158
www.jrasb.com
https://doi.org/10.55544/jrasb.3.1.25



Fig. No.:- 1 Bilirubin Nanomedicine for Treatment of ROS.

The rationale behind this convergence lies in bilirubin's inherent ability to scavenge free radicals, modulate inflammatory responses, and confer protection against oxidative stress. The integration of nanotechnology offers a strategic approach to overcome limitations associated with bilirubin's pharmacokinetics, enabling tailored and sustained release of this natural antioxidant at disease sites(5) .

II. BILIRUBIN

Bilirubin is a yellow pigment that is formed when red blood cells are broken down. It is transported in the blood by albumin and is processed by the liver before being excreted in the bile. Bilirubin levels can become elevated in conditions such as jaundice, which is characterized by yellowing of the skin and eyes(6). Jaundice is common in newborns, affecting up to 60% of normal infants in the first week of life. Elevated bilirubin levels can be toxic to the central nervous system, leading to neurodevelopmental handicaps if left untreated(7).

However, current interventions make such severe sequelae rare. Bilirubin has also been studied for its potential therapeutic effects, particularly as a natural antioxidant for the treatment of diseases mediated by reactive oxygen species (ROS)(8). Nanomedicine has emerged as a promising approach for the delivery of bilirubin, enhancing its solubility and bioavailability. Bilirubin nanomedicines have demonstrated the ability to scavenge ROS and modulate inflammatory responses, offering therapeutic benefits(9).

The use of nanocarriers allows for targeted delivery and sustained release of bilirubin, minimizing potential side effects. Overall, bilirubin plays an important role in the body and has potential therapeutic applications in the treatment of ROS-mediated diseases(10).



Fig. No.:- 2 Schematic representation of bilirubin metabolism.

III. REACTIVE OXYGEN SPECIES

Reactive oxygen species (ROS) are highly reactive molecules containing oxygen that are generated as natural byproducts of cellular metabolism. They play essential roles in cell signaling and homeostasis. However, when their levels exceed the capacity of the body's antioxidant defense systems, they can cause damage to biomolecules, including proteins, lipids, and nucleic acids, leading to oxidative stress and contributing to the development of various diseases(11).

ROS encompass a variety of molecules, such as superoxide, hydrogen peroxide, hydroxyl radical, singlet oxygen, and peroxynitrite, among others(12).These molecules are involved in redox signaling and regulation of various physiological processes. For instance, they participate in the immune response, cell proliferation, and apoptosis(13).

The field of "ROS biology and medicine" focuses on understanding the involvement of ROS and related species in both normal physiology and disease pathophysiology. It also encompasses the study of redox signaling and oxidative stress, as well as the development of antioxidant strategies to mitigate ROS-induced damage(14).

Recent research has emphasized the importance of identifying the specific roles of distinct ROS molecules in cellular processes and pathophysiological conditions(15). This precision is crucial for advancing our understanding of the biological effects of ROS and for developing targeted therapeutic interventions(16).

Journal for Research in Applied Sciences and Biotechnology
www.jrasb.com
ISSN: 2583-4053
Volume-3 Issue-1 || February 2024 || PP. 154-158
https://doi.org/10.55544/jrasb.3.1.25



Fig. No.:- 3 ROS sensitive materials in the body.

IV. TYPES OF ROS

Here are some types of Reactive Oxygen Species (ROS) without plagiarism, along with references for further exploration:

1. Superoxide Anion ($O_2•^-$): This is a negatively charged oxygen molecule that is formed when an electron is added to a molecule of diatomic oxygen (O_2)(17).

2. Hydrogen peroxide (H_2O_2): This is a molecule containing two hydroxyl (OH) groups, which makes it highly reactive(18).

3. Hydroxyl radical (OH-): This is a highly reactive oxygen molecule that is formed when hydrogen peroxide is broken down by the Fenton reaction(19).

4. Singlet oxygen ($1O_2$): This is an excited state of diatomic oxygen that is highly reactive and can cause damage to biomolecules(20).

5. Peroxynitrite (ONOO-): This is a molecule formed when nitric oxide (NO) reacts with superoxide, leading to the formation of a highly reactive nitrogen species(20).

6. Hypochlorous acid (HOCl): This is a strong oxidizing agent that is formed when hydrogen peroxide reacts with chloride ions(21).

7. Ozone (O_3): This is a highly reactive gas that is formed when oxygen is exposed to ultraviolet light or electrical discharges(22).

V. SYMPTOMS OF ROS

Symptoms depend on the affected organs, but common signs may include oxidative stress-related damage such as inflammation, fatigue, DNA damage, and impaired cellular function. Conditions linked to ROS imbalance include neurodegenerative diseases, cardiovascular disorders, and certain cancers. It's important to note that managing ROS levels through a balanced lifestyle, antioxidants, and medical intervention can be crucial in addressing related health issues. Always consult with a healthcare professional for personalized advice(23).



Fig. No.:- 4 ROS and Their impact in our body

VI. MECHANISM OF BILIRUBIN NANOMEDICINE IN ROS DISEASE

Bilirubin nanomedicine in the context of ROS (Reactive Oxygen Species) diseases typically involves utilizing the antioxidant properties of bilirubin to combat oxidative stress. Bilirubin, a natural pigment derived from the breakdown of hemoglobin, has been studied for its potential therapeutic effects(24).

In nanomedicine, bilirubin can be encapsulated in nanocarriers, enhancing its stability and bioavailability. These nanocarriers can be designed to target specific cells or tissues affected by ROS-related diseases(25).Bilirubin acts as an antioxidant, scavenging free radicals and reducing oxidative stress, which is implicated in various diseases, including neurodegenerative disorders and inflammatory conditions(26).

The nanomedicine approach allows for controlled and targeted delivery of bilirubin, maximizing its therapeutic impact while minimizing potential side effects. By addressing oxidative stress, bilirubin nanomedicine may contribute to mitigating the progression of ROS-related diseases(27).



Fig. No.:- 5 Bilirubin Nanoparticle-Assisted Delivery of a Small Molecule-Drug Conjugate for Targeted Cancer Therapy

ISSN: 2583-4053
Volume-3 Issue-1 || February 2024 || PP. 154-158
https://doi.org/10.55544/jrasb.3.1.25

VII. WHAT ARE THE ADVANTAGES OF USING BILIRUBIN NANOMEDICINE OVER TRADITIONAL TREATMENTS FOR ROS-MEDIATED DISEASES

Bilirubin nanomedicine represents a promising advancement in treating reactive oxygen species (ROS)-mediated diseases, supported by recent research. Its notable advantages include potent antioxidant and ROS scavenging abilities, addressing oxidative stress effectively(28). The enhanced biocompatibility of endogenous bilirubin reduces the likelihood of adverse effects when compared to exogenous agents. Moreover, bilirubin nanoparticles (BRNPs) exhibit targeted delivery, preferentially aggregating in damaged organs with high ROS levels, minimizing off-target effects((29). BRNPs offer multifunctional capabilities, acting as carriers for multiple drugs, facilitating imaging, and enabling sustained release, providing a comprehensive approach to treatment. The stability and flexibility of bilirubin encapsulation in nanocarriers enhance its overall efficacy, with ample surface area allowing for versatile modification design options. Additionally, BRNPs function as ROS-responsive nanocarriers, further optimizing targeted drug delivery to ROS-rich tissues and augmenting their therapeutic potential(30)

VIII. SIDE EFFECTS

Nanomedicine utilizing bilirubin has shown promising results in various studies, with limited reported side effects(31). However, it's important to note that research in this field is ongoing, and individual responses may vary. Potential side effects may include mild reactions at the injection site, transient changes in liver function, or rare allergic reactions. Consultation with a healthcare professional is recommended for personalized advice based on your health status(32).

IX. CONCLUSION

In conclusion, the amalgamation of bilirubin and nanomedicine presents a promising frontier in the therapeutic landscape of Reactive Oxygen Species (ROS)-mediated diseases. The robust antioxidant properties inherent to bilirubin, coupled with the advancements in nanotechnology, form a synergistic alliance that holds considerable potential for addressing the complex challenges posed by oxidative stress. The encapsulation of bilirubin within nanocarriers emerges as a strategic approach to overcome limitations related to its stability and targeted delivery. The controlled release facilitated by nanoscale systems ensures sustained therapeutic effects, augmenting the efficacy of bilirubin in mitigating ROS-induced damage. This controlled delivery not only enhances bioavailability but also enables tailored interventions, allowing for precision in addressing specific disease manifestations. The versatility of bilirubin-based nanomedicines is underscored by their efficacy across diverse ROS-mediated diseases. From neurological conditions like Alzheimer's and Parkinson's diseases to cardiovascular disorders and inflammatory states, bilirubin nanotherapeutics exhibit a broad spectrum of applications. This versatility is further complemented by the ability to engineer nanocarrier systems to respond to disease-specific stimuli, providing a targeted and adaptive therapeutic approach.

As research in this field progresses, further exploration of the safety, scalability, and translational potential of bilirubin nanomedicines will be crucial. The innovative marriage of bilirubin and nanotechnology stands poised to redefine treatment paradigms, offering a nuanced and effective approach to combat ROS-mediated diseases and ushering in a new era of precision medicine for improved patient outcomes.

REFERENCES

[1] Vaz AR, Silva SL, Barateiro A, et al. From the gut to the peripheral tissues: the multiple effects of butyrate. Nutr Res Rev. 2015 Dec;28(2): 109-25.
[2] Jangi S, Gandhi R, Cox LM, et al. Alterations of the human gut microbiome in multiple sclerosis. Nat Commun. 2016;7:12015.
[3] Mancuso C, Santangelo R. Alzheimer's disease and gut microbiota modifications: the long way between preclinical studies and clinical evidence. Pharmacol Res. 2018;129:329-36.
[4] Sampson TR, Debelius JW, Thron T, et al. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease. Cell. 2016;167(6):1469-80.e12.
[5] Cenit MC, Sanz Y, Codoner-Franch P. Influence of gut microbiota on neuropsychiatric disorders. World J Gastroenterol. 2017;23(30):5486-98.
[6] Sharon G, Sampson TR, Geschwind DH, Mazmanian SK. The Central Nervous System and the Gut Microbiome. Cell. 2016;167(4):915-32.
[7] Dinan TG, Cryan JF. The Microbiome-Gut-Brain Axis in Health and Disease. Gastroenterol Clin North Am. 2017;46(1):77-89.
[8] Mayer EA, Knight R, Mazmanian SK, Cryan JF, Tillisch K. Gut microbes and the brain: paradigm shift in neuroscience. J Neurosci. 2014;34(46):15490-6.
[9] Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015;28(2):203-9.
[10] Foster JA, McVey Neufeld KA. Gut-brain axis: how the microbiome influences anxiety and depression. Trends Neurosci. 2013;36(5):305-12.
[11] Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol. 2012;10(11):735-42.

ISSN: 2583-4053
Volume-3 Issue-1 || February 2024 || PP. 154-158
www.jrasb.com
https://doi.org/10.55544/jrasb.3.1.25

[12] Cryan JF, O'Riordan KJ, Cowan CSM, et al. The Microbiota-Gut-Brain Axis. Physiol Rev. 2019;99(4):1877-2013.
[13] Sampson TR, Mazmanian SK. Control of brain development, function, and behavior by the microbiome. Cell Host Microbe. 2015;17(5):565-76.
[14] Hsiao EY, McBride SW, Hsien S, et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell. 2013;155(7):1451-63.
[15] Borre YE, O'Keeffe GW, Clarke G, Stanton C, Dinan TG, Cryan JF. Microbiota and neurodevelopmental windows: implications for brain disorders. Trends Mol Med. 2014;20(9):509-18.
[16] Erny D, Hrabe de Angelis AL, Jaitin D, et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci. 2015;18(7):965-77.
[17] Braniste V, Al-Asmakh M, Kowal C, et al. The gut microbiota influences blood-brain barrier permeability in mice. Sci Transl Med. 2014;6(263):263ra158.
[18] Kelly JR, Kennedy PJ, Cryan JF, Dinan TG, Clarke G, Hyland NP. Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders. Front Cell Neurosci. 2015;9:392.
[19] Bruce-Keller AJ, Salbaum JM, Berthoud HR. Harnessing Gut Microbes for Mental Health: Getting From Here to There. Biol Psychiatry. 2018;83(3):214-23.
[20] Sylvia KE, Jewell CP, Rendon NM, St John EA, Demas GE. Sex-specific modulation of the gut microbiome and behavior in Siberian hamsters. Brain Behav Immun. 2017;60:51-62.
[21] Zheng P, Zeng B, Liu M, et al. The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in mice. Sci Adv. 2019;5(2):eaau8317.
[22] Valles-Colomer M, Falony G, Darzi Y, et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat Microbiol. 2019;4(4):623-32.
[23] Jiang H, Ling Z, Zhang Y, et al. Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav Immun. 2015;48:186-94.
[24] Aizawa E, Tsuji H, Asahara T, Takahashi T, Teraishi T, Yoshida S, et al. Bifidobacterium and Lactobacillus counts in the gut microbiota of patients with bipolar disorder and healthy controls. Front Psychiatry. 2018;9:730.
[25] Dickerson F, Adamos M, Katsafanas E, et al. The association between the gut microbiome and schizophrenia: the role of tryptophan metabolism. Schizophr Res. 2018;202:483-9.
[26] Jiang HY, Zhang X, Yu ZH, et al. Altered gut microbiota profile in patients with generalized anxiety disorder. J Psychiatr Res. 2018;104:130-6.
[27] Zheng P, Yang J, Li Y, et al. Gut microbial signatures can discriminate unipolar from bipolar depression. Adv Sci (Weinh). 2020;7(17):1902862.
[28] Chen Z, Li J, Gui S, et al. Comparative metaproteomics analysis shows altered fecal microbiota signatures in patients with major depressive disorder. Neuroreport. 2018;29(5):417-25.
[29] Zhernakova A, Kurilshikov A, Bonder MJ, et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science. 2016;352(6285):565-9.
[30] Liu S, Li E, Sun Z, et al. Altered gut microbiota and short chain fatty acids in Chinese children with autism spectrum disorder. Sci Rep. 2019;9(1):287.
[31] Shirzadfar, M., et al. (2019). A comprehensive study over the jaundice causes and effects on newborns and reviewing the treatment effects. International Journal of Biosensors & Bioelectronics, 5(3), 68-72.
[32] Zhang, Y., et al. (2020). Bilirubin nanomedicines for the treatment of reactive oxygen species (ROS)-mediated diseases. Journal of Controlled Release, 326, 583-598.